Log In
Print this Print this

otelixizumab (TRX4) (formerly ChAglyCD3)

  Manage Alerts
Collapse Summary General Information
Company BTG plc
DescriptionHumanized anti-CD3 mAb
Molecular Target CD3
Mechanism of ActionBinds CD3; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today